Genexine, Inc. (095700.KQ)
KRW 5590.0
(-3.79%)
KRW 5590.0
(-3.79%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 79.68 Billion KRW | -26.13% |
| 2022 | 107.87 Billion KRW | -5.03% |
| 2021 | 113.59 Billion KRW | 88.14% |
| 2020 | 60.37 Billion KRW | -1.46% |
| 2019 | 61.26 Billion KRW | 12.82% |
| 2018 | 54.3 Billion KRW | 102.44% |
| 2017 | 26.82 Billion KRW | -5.77% |
| 2016 | 28.46 Billion KRW | 74.28% |
| 2015 | 16.33 Billion KRW | 0.0% |
| 2012 | 17.55 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 77.32 Billion KRW | -2.96% |
| 2024 Q2 | 78.41 Billion KRW | 1.41% |
| 2023 Q3 | 97.38 Billion KRW | 1.78% |
| 2023 Q2 | 95.68 Billion KRW | -2.6% |
| 2023 Q1 | 98.23 Billion KRW | -8.93% |
| 2023 FY | 79.68 Billion KRW | -26.13% |
| 2023 Q4 | 79.68 Billion KRW | -18.18% |
| 2022 Q2 | 96.85 Billion KRW | 1.55% |
| 2022 Q1 | 95.37 Billion KRW | -16.04% |
| 2022 FY | 107.87 Billion KRW | -5.03% |
| 2022 Q4 | 107.87 Billion KRW | 0.95% |
| 2022 Q3 | 106.85 Billion KRW | 10.33% |
| 2021 Q3 | 78.17 Billion KRW | 7.93% |
| 2021 Q4 | 113.59 Billion KRW | 45.3% |
| 2021 FY | 113.59 Billion KRW | 88.14% |
| 2021 Q1 | 58.21 Billion KRW | -3.57% |
| 2021 Q2 | 72.43 Billion KRW | 24.41% |
| 2020 Q2 | 61.47 Billion KRW | -5.48% |
| 2020 FY | 60.37 Billion KRW | -1.46% |
| 2020 Q4 | 60.37 Billion KRW | 69.62% |
| 2020 Q3 | 35.59 Billion KRW | -42.1% |
| 2020 Q1 | 65.03 Billion KRW | 6.15% |
| 2019 Q4 | 61.26 Billion KRW | 0.0% |
| 2019 FY | 61.26 Billion KRW | 12.82% |
| 2018 FY | 54.3 Billion KRW | 102.44% |
| 2017 FY | 26.82 Billion KRW | -5.77% |
| 2016 FY | 28.46 Billion KRW | 74.28% |
| 2015 FY | 16.33 Billion KRW | 0.0% |
| 2013 Q3 | 18.07 Billion KRW | 0.0% |
| 2012 FY | 17.55 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Co., Ltd. | 169.47 Billion KRW | 52.983% |
| iNtRON Biotechnology, Inc. | 1.88 Billion KRW | -4137.64% |
| BINEX Co., Ltd. | 75.68 Billion KRW | -5.281% |
| Bioneer Corporation | 80.61 Billion KRW | 1.151% |
| Anterogen.Co.,Ltd. | 19.98 Billion KRW | -298.679% |
| MEDIPOST Co., Ltd. | 135.73 Billion KRW | 41.295% |
| CrystalGenomics, Inc. | 97.82 Billion USD | 18.543% |
| Helixmith Co., Ltd | 73.55 Billion KRW | -8.327% |
| Chabiotech Co.,Ltd. | 1069.23 Billion KRW | 92.548% |
| Medy-Tox Inc. | 137.14 Billion KRW | 41.897% |
| Peptron, Inc. | 16.36 Billion KRW | -386.793% |
| Amicogen, Inc. | 248.12 Billion KRW | 67.886% |
| HLB Therapeutics Co.,Ltd. | 29.27 Billion KRW | -172.179% |
| LegoChem Biosciences, Inc. | 41.28 Billion KRW | -93.026% |
| ALTEOGEN Inc. | 108.25 Billion KRW | 26.395% |
| PharmaResearch Co., Ltd. | 73.08 Billion KRW | -9.025% |
| SillaJen, Inc. | 19.4 Billion KRW | -310.717% |
| JETEMA, Co., Ltd. | 179.09 Billion KRW | 55.507% |
| OliX Pharmaceuticals,Inc | 52.48 Billion KRW | -51.809% |
| Genomictree Inc. | 7.81 Billion KRW | -919.973% |
| MedPacto, Inc. | 9.56 Billion KRW | -733.005% |
| D&D Pharmatech | 23.98 Billion KRW | -232.211% |
| EASY BIO,Inc. | 105.86 Billion KRW | 24.734% |
| GI Innovation, Inc. | 9.63 Billion KRW | -726.913% |